

6. References

- ¹ World Health Organization. (2022, November 28). *COVID-19 Vaccines with WHO Emergency Use Listing*. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Retrieved January 24, 2023, from <https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued>
- ² World Health Organization. (n.d.). *COVID-19 vaccine tracker and landscape*. Retrieved January 24, 2023, from <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>
- ³ World Health Organization. (2022, September 28). *Medicines/Finished Pharmaceutical Products*. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Retrieved January 24, 2023, from <https://extranet.who.int/pqweb/content/prequalified-lists/medicines?label=>
- ⁴ World Health Organization. (2022, March 9). *Medical Product Alert N°2/2022: Falsified DESREM (Remdesivir)*. Retrieved January 25, 2023, from [https://www.who.int/news/item/09-03-2022-medical-product-alert-n-2-2022-falsified-desrem-\(remdesivir\)](https://www.who.int/news/item/09-03-2022-medical-product-alert-n-2-2022-falsified-desrem-(remdesivir))

-
- ⁵ World Health Organization. (2021, March 26). *Medical Product Alert N°2/2021: Falsified COVID-19 Vaccine BNT162b2*. Retrieved January 25, 2023, from <https://www.who.int/news/item/26-03-2021-medical-product-alert-n-2-2021-falsified-covid-19-vaccine-bnt162b2>
- ⁶ *Pharmacovigilance*. (2022, August 30). World Health Organization (WHO). <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance>
- ⁷ World Health Organization (WHO). (2018). *COVID-19 vaccines: safety surveillance manual*. <https://apps.who.int/iris/handle/10665/338400>
- ⁸ *131 newly registered nurses undergo COVID-19 vaccination training*. (2021, June 29). <https://solomons.gov.sb/131-newly-registered-nurses-undergo-covid-19-vaccination-training/>
- ⁹ *COVID-19 technical assistance in the region: vaccine programs / ARIA*. (n.d.). <https://regionalimmunisationalliance.org.au/our-work/covid-19-technical-assistance-region-vaccine-programs>
- ¹⁰ *NCIRS technical staff working in the region / NCIRS*. (n.d.). <https://www.ncirs.org.au/regional-and-global-collaborations/ncirs-technical-staff-working-region>

¹¹ MPP. (2022, December 7). *MOLNUPIRAVIR (MOL)*.

<https://medicinespatentpool.org/licence-post/molnupiravir-mol>

¹² *The Access to COVID-19 Tools (ACT) Accelerator*. (2022, October 28).

<https://www.who.int/initiatives/act-accelerator>

¹³ World Health Organization (WHO). (2019). *PACIFIC ISLAND MEETING ON SUBREGIONAL REGULATORY SYSTEMS FOR MEDICINES*.

https://www.who.int/docs/default-source/wpro---documents/dps/other-meeting-documents/rs-2019-ge-10-fji-eng.pdf?sfvrsn=bf2363e0_2

¹⁴ Vargesson, N. (2015). Thalidomide-induced teratogenesis: History and mechanisms. *Birth Defects Research Part C: Embryo Today: Reviews*, 105(2), 140–156.

<https://doi.org/10.1002/bdrc.21096>

¹⁵ *Lagevrio 200 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc)*.

(n.d.). <https://www.medicines.org.uk/emc/product/13044>

¹⁶ U.S. Food and Drug Administration. (2021). *FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID*.

<https://www.fda.gov/media/155050/download>

¹⁷ Linger, M., & Martin, J. (2018). Pharmacovigilance and expedited drug approvals.

Australian Prescriber, 41(2), 50–53. <https://doi.org/10.18773/austprescr.2018.010>

-
- ¹⁸ Therapeutic Goods Administration (TGA). (2021, January 21). *Other pharmacovigilance requirements*. Australian Recommendations and Requirements. Retrieved January 11, 2023, from <https://www.tga.gov.au/resources/resource/guidance/pharmacovigilance-responsibilities-medicine-sponsors/other-pharmacovigilance-requirements>
- ¹⁹ Therapeutic Goods Administration (TGA). (2019, March 29). *When an RMP is required: Australian requirements and recommendations*. Retrieved January 11, 2023, from <https://www.tga.gov.au/resources/resource/guidance/risk-management-plans-medicines-and-biologicals/when-rmp-required>
- ²⁰ Therapeutic Goods Administration (TGA). (2017). *Pharmacovigilance inspection program: Guidance for medicine sponsors version 1.0*. Retrieved January 11, 2023, from <https://www.tga.gov.au/resources/publication/publications/pharmacovigilance-inspection-program-guidance-medicine-sponsors>
- ²¹ Therapeutic Goods Administration (TGA). (2022, September 23). *TGA provisionally approves Pfizer Australia Pty Ltd's COVID-19 treatment nirmatrelvir + ritonavir (PAXLOVID)* [Press release]. <https://www.tga.gov.au/tga-provisionally-approves-pfizer-australia-pty-ltds-covid-19-treatment-nirmatrelvir-ritonavir-paxlovid>
- ²² Therapeutic Goods Administration (TGA). (2022a, September 9). *TGA provisionally approves Merck Sharp & Dohme (Australia) Pty Ltd's oral COVID-19 treatment, LAGEVRIO (molnupiravir)* [Press release]. <https://www.tga.gov.au/tga-provisionally->

approves-merck-sharp-dohme-australia-pty-ltds-oral-covid-19-treatment-lagevrio-
molnupiravir

²³ Therapeutic Goods Administration (TGA). (2022, November 1). *Updated eligibility for oral COVID-19 treatments*. Retrieved January 11, 2023, from <https://www.health.gov.au/health-alerts/covid-19/treatments/eligibility>

²⁴ Borys, S. (2022, July 11). COVID-19 antiviral treatments to become available to more Australians. *ABC News*. <https://www.abc.net.au/news/2022-07-10/covid19-antiviral-treatment-available-to-more-australians-/101224702>

²⁵ Therapeutic Goods Administration (TGA). (2022). Paxlovid. In *Australian Prescription Medicine Decision Summaries*. Retrieved January 11, 2023, from <https://www.tga.gov.au/resources/auspmd/paxlovid>

²⁶ Therapeutic Goods Administration (TGA). (2022). Lagevrio. In *Australian Prescription Medicine Decision Summaries*. Retrieved January 11, 2023, from <https://www.tga.gov.au/resources/auspmd/paxlovid>

²⁷ Ministry Of Health Brunei Darussalam. (2018). *BRUNEI DARUSSALAM PHARMACOVIGILANCE GUIDELINES*. Retrieved January 11, 2023, from <https://www.moh.gov.bn/Shared%20Documents/Importation%20of%20Medicines/Brunei%20Darussalam%20Pharmacovigilance%20Guidelines%2031.7.18.pdf>

²⁸ Ministry Of Health Brunei Darussalam. (2022, March 26). *PAXLOVID oral antiviral drug arrived in Brunei Darussalam* [Press release].

<https://www.moh.gov.bn/Lists/Latest%20news/NewDispForm.aspx?ID=1198&ContentTypeId=0x0104009A3003A09F8D6E42981D262E322516A2>

²⁹ Department of Drugs and Food. (n.d.). *PV Organization*. Retrieved January 11, 2023, from https://www.ddfcambodia.com/pv_center/pv-organization.html

³⁰ Department of Drugs and Food/ Essential Drug Bureau. (n.d.). *CAMBODIAN PHARMACOVIGILANCE CENTER IN AMFm PROJECT PHASE 1: Active pharmacovigilance monitoring with a special focus on AMFm*. Retrieved January 11, 2023, from <https://www.ddfcambodia.com/images/pharmacovigilanceguidanceforadrmonitoringofact.pdf>

³¹ Pharmacovigilance Advisory Committee Cambodian Pharmacovigilance Center. (2015). *OPERATING GUIDELINES FOR THE PHARMACOVIGILANCE ADVISORY COMMITTEE (PVAC)*. Retrieved January 11, 2023, from <https://www.ddfcambodia.com/images/PVAC%20Eng.pdf>

³² Health Sciences Authority (HSA). (2022a, February 3). *HSA Grants Interim Authorisation for Paxlovid™, the First Oral Medicine for Treatment of COVID-19 Infection* [Press release]. <https://www.hsa.gov.sg/announcements/press-release/interimauth-paxlovid/>

³³ DKSH Cambodia. (n.d.). *DKSH Cambodia*. Retrieved January 12, 2023, from

<https://www.dksh.com/kh-en/home>

³⁴ *Centre of Regulatory Excellence In-Country Training on Pharmacovigilance*. (2017).

Retrieved January 12, 2023, from [https://www.duke-](https://www.duke-nus.edu.sg/docs/librariesprovider5/default-document-library/ict-report_pv-lao_2017.pdf?sfvrsn=970d0090_0)

[nus.edu.sg/docs/librariesprovider5/default-document-library/ict-report_pv-](https://www.duke-nus.edu.sg/docs/librariesprovider5/default-document-library/ict-report_pv-lao_2017.pdf?sfvrsn=970d0090_0)

[lao_2017.pdf?sfvrsn=970d0090_0](https://www.duke-nus.edu.sg/docs/librariesprovider5/default-document-library/ict-report_pv-lao_2017.pdf?sfvrsn=970d0090_0)

³⁵ *Medicinal product regulation and product liability in Cambodia: overview*. (n.d.).

THOMSON REUTERS PRACTICAL LAW. Retrieved January 12, 2023, from

[https://uk.practicallaw.thomsonreuters.com/w-016-](https://uk.practicallaw.thomsonreuters.com/w-016-6538?transitionType=Default&contextData=(sc.Default)&firstPage=true)

[6538?transitionType=Default&contextData=\(sc.Default\)&firstPage=true](https://uk.practicallaw.thomsonreuters.com/w-016-6538?transitionType=Default&contextData=(sc.Default)&firstPage=true)

³⁶ Department Of Drugs And Food Essential Drugs Bureau. (2020). *GUIDELINE FOR*

ADVERSE DRUG REACTIONS (ADR) MONITORING AND RELATED MATTERS.

Retrieved January 12, 2023, from

[https://www.ddfcambodia.com/images/Guideline%20for%20ADR%20Monitoring%2](https://www.ddfcambodia.com/images/Guideline%20for%20ADR%20Monitoring%20and%20Related%20Matters%20final.pdf)

[0and%20Related%20Matters%20final.pdf](https://www.ddfcambodia.com/images/Guideline%20for%20ADR%20Monitoring%20and%20Related%20Matters%20final.pdf)

³⁷ Department Of Drugs And Food Essential Drugs Bureau. (2020). *Pharmacovigilance*

Guideline for National Programs for Intervention in Public Health. Retrieved January

12, 2023, from [https://www.ddfcambodia.com/images/PV%20guideline%20English-](https://www.ddfcambodia.com/images/PV%20guideline%20English-PH.pdf)

[PH.pdf](https://www.ddfcambodia.com/images/PV%20guideline%20English-PH.pdf)

-
- ³⁸ Cambodia authorises Paxlovid Covid pill for patients 12 and over. (2022, May 29). *The Star*. Retrieved January 12, 2023, from <https://www.thestar.com.my/aseanplus/aseanplus-news/2022/05/29/cambodia-authorises-paxlovid-covid-pill-for-patients-12-and-over>
- ³⁹ Residents rush to buy Covid medicine at the Ministry of Posts as the omicron virus is spreading. (n.d.). *The Cambodia Daily*. Retrieved February 22, 2022, from <https://www.cambodiadaily.com/2022/02/22/11/07/60515/>
- ⁴⁰ The ministry claims that Molnupiravir is used for treatment, not to prevent Covid. (2022, March 25). *VOD*. Retrieved January 11, 2023, from https://www.vodkhmer.news/2022/03/12/moh_claims_that_molnupiravir_used_only/
- ⁴¹ *Decree of the Ministry of Health of the People's Republic of China*. (2011). http://english.nmpa.gov.cn/2019-12/14/c_432227_2.htm
- ⁴² Song, H., Pei, X., Liu, Z., Shen, C., Sun, J., Liu, Y., Zhou, L., Sun, F., & Xiao, X. (2022). Pharmacovigilance in China: Evolution and future challenges. *British Journal of Clinical Pharmacology*. <https://doi.org/10.1111/bcp.15277>
- ⁴³ *The State Food and Drug Administration approved the import registration of Pfizer's new coronavirus treatment drug nirmatrelvir tablets/ritonavir tablets combination packaging*. (2022). National Medical Products Administration (NMPA). Retrieved January 12, 2023, from

<https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20220212085753142.html>

⁴⁴ *The State Food and Drug Administration approved the import registration of Merck's new coronavirus treatment drug Monogrovir Capsules with emergency conditions.* (2022).

National Medical Products Administration (NMPA). Retrieved January 12, 2023, from

<https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20220212085753142.html>

⁴⁵ China approves first homegrown COVID antiviral. (2022, July 26). *Nature*. Retrieved January 11, 2023, from https://www.nature.com/articles/d41586-022-02050-x?error=cookies_not_supported&code=4ad1e3e9-5c06-4f64-8c1a-128cf27409e5

⁴⁶ Chan, T. Y. (2014). Pharmacovigilance in Hong Kong. *Mann's Pharmacovigilance*, 259–261. <https://doi.org/10.1002/9781118820186.ch15b>

⁴⁷ Food and Health Bureau Hong Kong. (2007). *Report of the Review Committee on Regulation of Pharmaceutical Products in Hong Kong*. Retrieved January 12, 2023, from https://www.healthbureau.gov.hk/download/press_and_publications/otherinfo/100105_pharm_review/en_full_report.pdf

-
- ⁴⁸ Pharmacy and Poisons Board of Hong Kong. (2021). *Code of Practice for Licensed Manufacturers and Registered Authorized Persons*. Retrieved January 12, 2023, from https://www.ppbhk.org.hk/eng/files/PPB_COP_ML.pdf
- ⁴⁹ Pharmacy and Poisons Board. (2022). *List of registered pharmaceutical products indicated for the treatment or prevention of coronavirus disease (COVID-19)*. Retrieved January 12, 2023, from https://www.ppbhk.org.hk/files/List_of_registered_pharmaceutical_products_indicated_for_the_treatment_or_prevention_of_coronavirus_disease.pdf
- ⁵⁰ Drug Administration. (n.d.). *Announcement of Adverse Drug Reaction and Quality Monitoring Data*. Retrieved January 13, 2023, from <https://www.gov.mo/zh-hant/services/ps-1572/>
- ⁵¹ Pharmaceutical Administration Bureau Macao SAR Government. (n.d.). *Introduction and Guidelines of ADR Reporting System*. <https://www.isaf.gov.mo/wp-content/uploads/2022/04/%E8%97%A5%E7%89%A9%E4%B8%8D%E8%89%AF%E5%8F%8D%E6%87%89%E9%80%9A%E5%A0%B1%E7%B3%BB%E7%B5%B1%E4%BB%8B%E7%B4%B9%E5%8F%8A%E9%A0%88%E7%9F%A5.pdf>
- ⁵² Macau Special Administrative District. (2022). *Emergency Response Plan for COVID-19 pandemic*. <https://www.ssm.gov.mo/docs2/file/p/21928/ch>

⁵³ Department of Drugs and Food, Cambodia. (n.d.). *Department of Hospital Medicine Management*. Retrieved January 13, 2023, from <http://www.fdd.gov.la/content.php?contID=11>

⁵⁴ *Centre of Regulatory Excellence In-Country Training on Pharmacovigilance*. (2017). Retrieved January 12, 2023, from https://www.duke-nus.edu.sg/docs/librariesprovider5/default-document-library/ict-report_pv-lao_2017.pdf?sfvrsn=970d0090_0

⁵⁵ *Regulatory Systems on Ensuring Access to Quality Medicines: Country Reports*. (2021). Japan International Corporation of Welfare Services (JICWELS). Retrieved January 12, 2023, from [https://jicwels.or.jp/files/CountryReports/medicine/2020\(R02\)_%E8%96%AC%E4%BA%8B%E8%A1%8C%E6%94%BF_R.pdf](https://jicwels.or.jp/files/CountryReports/medicine/2020(R02)_%E8%96%AC%E4%BA%8B%E8%A1%8C%E6%94%BF_R.pdf)

⁵⁶ *Guideline for medicines*. (n.d.). Ministry of Health, Lao PRD., Food and Drug Department. Retrieved January 13, 2023, from http://www.fdd.gov.la/content_en.php?contID=40

⁵⁷ Thanabouasy, P. (2022, March 31). More Factories Begin Producing Molnupiravir Covid-19 Medication in Laos. *Laotian Times*. Retrieved January 11, 2023, from <https://laotiantimes.com/2022/03/31/more-factories-begin-produce-molnupiravir-covid-19-medication-in-laos/>

-
- ⁵⁸ Department of Food and Drugs (FDD) of the Ministry of Health. (2022). *Notice letter: Monitoring and surveillance of the distribution of COVID-19 drug products and the AgRDT rapid test for COVID-19 infection*. Retrieved January 12, 2023, from <http://www.fdd.gov.la/download/documents/ແຈ້ງການ%205002.pdf>
- ⁵⁹ National Pharmaceutical Regulatory Agency (NPRA). (2019, March 21). *Introduction to MADRAC*. Retrieved January 11, 2023, from <https://www.npra.gov.my/index.php/en/about/malaysian-adverse-drug-reactions-advisory-committee-madrac/madrac-introduction>
- ⁶⁰ Burud, I., Daher, A. M., Din, H. B., Agarwal, P., Zakaria, J., & Agarwal, R. (2021). Knowledge, attitudes, and practices related to adverse drug reaction reporting by healthcare professionals in a tertiary hospital in Malaysia. *Journal of Applied Pharmaceutical Science*. <https://doi.org/10.7324/japs.2021.1101011>
- ⁶¹ Shaik Rahmat, S., & Karuppannan, M. (2021). Barriers to adverse drug reaction reporting in Malaysia: a narrative review based on theoretical domains framework. *Journal of Pharmaceutical Health Services Research*, 12(4), 626–632. <https://doi.org/10.1093/jphsr/rmab024>
- ⁶² National Pharmaceutical Regulatory Agency. (2021). *MALAYSIAN GUIDELINES ON GOOD PHARMACOVIGILANCE PRACTICES (GVP) FOR PRODUCT REGISTRATION HOLDERS*. Retrieved January 12, 2023, from <https://www.npra.gov.my/easyarticles/images/users/1047/Malaysian-Guidelines-on->

Good-Pharmacovigilance-Practices-GVP-For-Product-Registration-Holders-First-Edition-August-2021.pdf

⁶³ National Pharmaceutical Regulatory Agency Ministry of Health, Malaysia. (2022).

MALAYSIAN GUIDANCE DOCUMENT ON VOLUNTARY GOOD

PHARMACOVIGILANCE PRACTICES (GVP) INSPECTION. Retrieved January 12, 2023, from

<https://www.npra.gov.my/easyarticles/images/shared/FV/Guidelines/Finalised-Guidance-Documents-on-Voluntary-GVPI-14032022.pdf>

⁶⁴ COVID-19: PKBD gives conditional approval for the use of the antiviral pill

Molnupiravir. (2022, April 8). *Astro Awani*. Retrieved January 12, 2023, from

<https://www.astroawani.com/berita-malaysia/covid19-pkbd-beri-kelulusan-bersyarat-penggunaan-pil-antiviral-molnupiravir-355745>

⁶⁵ Paxlovid now available in private health facilities. (2022, June 21). *FMT*. Retrieved

January 12, 2023, from

<https://www.freemalaysiatoday.com/category/nation/2022/06/21/paxlovid-now-available-in-private-health-facilities/>

⁶⁶ Xian, L. J. (2022, June 8). Covid-19: Over 1,300 patients recovered after Paxlovid

treatment, says KJ. *The Star*.

⁷⁸
<https://www.thestar.com.my/news/nation/2022/06/08/covid-19-over-1300-patients-recovered-after-paxlovid-treatment-says-kj>

-
- ⁶⁷ Asian Development Bank (ADB). (2022). *SUPPORTING THE REGULATION OF MEDICINES IN MONGOLIA: EXPERIENCES, LESSONS LEARNED, AND FUTURE DIRECTIONS*. Retrieved January 12, 2023, from <https://www.adb.org/sites/default/files/publication/799026/eawp-049-supporting-regulation-medicines-mongolia.pdf>
- ⁶⁸ Medicine and Medical device Regulatory Agency (MMRA). (2021, August 11). *In cooperation with the WHO, a training was organized on the topic “STRENGTHENING PHARMACOVIGILANCE.”* Retrieved January 12, 2023, from <https://mmra.gov.mn/?id=200201>
- ⁶⁹ Zulzaga, Z., Myagmarsuren, E., Woerdenbag, H. J., & van Puijenbroek, E. P. (2021). Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we? *Journal of Pharmaceutical Policy and Practice*, 14(1). <https://doi.org/10.1186/s40545-021-00298-8>
- ⁷⁰ Medicine and Medical device Regulatory Agency (MMRA). (2013). *Procedures for recording and reporting information on drug side effects and safety*. <https://mmra.gov.mn/?id=200083>
- ⁷¹ Medicine and Medical device Regulatory Agency (MMRA). (2022). *Diagnosis and treatment guidelines*. <https://moh.gov.mn/uploads/files/682430683374a7af45dd405fdfa6dc1bf0a0f681.pdf>

⁷² Medsafe. (2020). *Guideline on the Regulation of Therapeutic Products in New Zealand*

Part 8: Pharmacovigilance.

<https://www.medsafe.govt.nz/regulatory/Guideline/GRTPNZ/part-8-pharmacovigilance.pdf>

⁷³ New Zealand Pharmacovigilance Center. (n.d.). *Reporting*. Retrieved January 12, 2023,

from <https://nzphvc.otago.ac.nz/reporting/#what-to-report>

⁷⁴ Medsafe. (2022, February 14). *Approval status of COVID-19 treatment applications.*

<https://www.medsafe.govt.nz/COVID-19/treatment-applications.asp>

⁷⁵ Site designed and developed by bka interactive ltd, Auckland, New Zealand

(www.bka.co.nz). (2022, December 20). *Antiviral medicines for COVID-19 infection.*

Health Navigator New Zealand.

<https://www.healthnavigator.org.nz/medicines/c/covid-19-treatments-antiviral-medicines/>

⁷⁶ Medsafe. (n.d.). *Summary of the risk management plan (version 1.2) for*

Paxlovid (nirmatrelvir/ritonavir). <https://www.medsafe.govt.nz/COVID-19/Paxlovid-RMP.pdf>

⁷⁷ Medsafe & Medsafe. (n.d.). *Summary of the risk management plan for Lagevrio*

(molnupiravir). Retrieved January 12, 2023, from

<https://www.medsafe.govt.nz/COVID-19/Lagevrio-RMP.pdf>

⁷⁸ *Ministry of Health PNG*. (n.d.). Retrieved January 13, 2023, from

<https://www.health.gov.pg/subindex.php?pharm=1>

⁷⁹ *Medicines and Cosmetics Regulation 2002*. (2006, November 25). PACIFIC ISLANDS

Legal Information INSTITUTE. Retrieved January 13, 2023, from

http://www.paclii.org/pg/legis/consol_act/macr2002297/

⁸⁰ Department Of Health, Office of the Secretary. (2021). *CIRCULAR No.51 OF 2021*.

Retrieved January 12, 2023, from https://www.health.gov.pg/param_pdf/51_2021.pdf

⁸¹ *Papua New Guinea: 2020 Digital Health Factsheet - Papua New Guinea*. (2021b, March

4). ReliefWeb. Retrieved January 13, 2023, from <https://reliefweb.int/report/papua-new-guinea/papua-new-guinea-2020-digital-health-factsheet>

⁸² Department of Health. (2011). *The Rules and Regulations Implementing Republic Act No.*

9711-The Food and Drug Administration Act of 2009. <https://www.dsap.ph/wp-content/uploads/2018/09/ph080en.pdf>

⁸³ Department of Health. (2011). *ADMINISTRATIVE ORDER No. 2011-0009 National*

Policy and Program on Pharmacovigilance. <https://www.fda.gov.ph/wp-content/uploads/2021/04/Administrative-Order-No.-2011-0009.pdf>

⁸⁴ Food and Drug Administration. (2020). *FDA Circular No.2020-003, Guidelines for*

Pharmaceutical Industry on Pharmacovigilance. <https://www.fda.gov.ph/wp-content/uploads/2020/02/FDA-Circular-No.2020-003.pdf>

-
- ⁸⁵ Food and Drug Administration. (2023). *FDA Circular No.2013-004, Post Market Surveillance of Authorized Drug Products*. <https://www.fda.gov.ph/wp-content/uploads/2021/08/FDA-Circular-No.2013-004.pdf>
- ⁸⁶ Food And Drug Administration. (2021). *Amended Emergency Use Authorization (EUA) for Casirivimab + Imdevimab*. Retrieved January 13, 2023, from <https://www.fda.gov.ph/wp-content/uploads/2021/11/Amended-EUA-Casirivimab-plus-Imdevimab-w.pdf>
- ⁸⁷ Kang, D. Y., Ahn, K. M., Kang, H. R., & Cho, S. H. (2017). Past, present, and future of pharmacovigilance in Korea. *Asia Pacific Allergy*, 7(3), 173. <https://doi.org/10.5415/apallergy.2017.7.3.173>
- ⁸⁸ *Adverse drug reaction consultation room*. (n.d.). Seoul National University Hospital. Retrieved January 13, 2023, from <https://dept.snuh.org/dept/DMC/content.do?menuId=008041>
- ⁸⁹ *Korea Disease Control and Prevention Agency (KDCA)*. (n.d.). Retrieved January 13, 2023, from <https://www.kdca.go.kr/index.es?sid=a3>
- ⁹⁰ PHARMACEUTICAL AFFAIRS ACT. (2016). In *Korea Legislation Research Institute*. https://elaw.klri.re.kr/eng_service/lawView.do?hseq=40196&lang=ENG

⁹¹ Ministry of Food and Drug Safety (MFDS). (2021). *Notification of Revision of Guidelines for Risk Management Plans for Pharmaceuticals (Complainant's Guide)*.

https://www.mfds.go.kr/brd/m_1060/view.do?seq=14890&srchFr=&srchTo=&srchWord=%EC%9C%84%ED%95%B4%EC%84%B1&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C9999&page=1

⁹² Ministry of Food and Drug Safety (MFDS). (2022). *MFDS approves emergency use of COVID-19 treatment "Laguebrio capsule."*

https://www.mfds.go.kr/brd/m_99/view.do?seq=46243&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

⁹³ Ministry of Food and Drug Safety. (2022, August 12). *MFDS Launches Pre-Review of Overseas Oral COVID-19 Treatment* [Press release].

https://www.mfds.go.kr/brd/m_99/view.do?seq=46611&srchFr=&srchTo=&srchWord=&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C1009&page=1

⁹⁴ Pharmaceuticals and Medical Devices Agency (PMDA). (n.d.-a). *Collection of contributions for safety measures, etc.* Retrieved January 13, 2023, from

<https://www.pmda.go.jp/safety/info-services/safety-contributions/0001.html>

⁹⁵ Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices. (1960, August 10). *Japanese Law Translation*.

<https://www.japaneselawtranslation.go.jp/en/laws/view/3213/en>

⁹⁶ Ministry of Health, Labour and Welfare. (2016). *Enforcement of Ministerial Ordinances Concerning Standards for Post-Marketing Safety Management of Pharmaceuticals, Quasi-drugs, Cosmetics, Medical Devices and Regenerative Medicine Products*.

https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryoku/iyakuhin/dl/140825_6-10.pdf

⁹⁷ Ministry of Health, Labour and Welfare. (2004, October 20). *Ministerial Ordinance on Standards for Conducting Post-Marketing Surveillance and Testing of Pharmaceuticals*. https://www.mhlw.go.jp/web/t_doc?dataId=81aa6623

⁹⁸ *Lagevrio*. (n.d.). Pharmaceuticals and Medical Devices Agency (PMDA). Retrieved January 13, 2023, from https://www.pmda.go.jp/RMP/www/170050/201cc49a-cc7d-482f-9178-d9c06f740932/170050_62500B6M1020_003RMP.pdf

⁹⁹ MSD. (2023). *Specific Usage Results Survey Interim Report*.

https://www.msdconnect.jp/wp-content/uploads/sites/5/2022/08/lagevrio_urs_interim_report_survey.pdf

¹⁰⁰ “*Lagevrio*” drug price listing, general distribution is now possible MSD. (2023, January 13). Nikkan Yakugyo. <https://nk.jiho.jp/article/173693>

¹⁰¹ *Nirmatrelvir / Ritonavir*. (n.d.). Pharmaceuticals and Medical Devices Agency (PMDA).

Retrieved January 13, 2023, from

[https://www.pmda.go.jp/RMP/www/672212/655a2ab8-21e4-403b-89a0-](https://www.pmda.go.jp/RMP/www/672212/655a2ab8-21e4-403b-89a0-8fb8c54f2371/672212_62501B5X1020_003RMP.pdf)

[8fb8c54f2371/672212_62501B5X1020_003RMP.pdf](https://www.pmda.go.jp/RMP/www/672212/655a2ab8-21e4-403b-89a0-8fb8c54f2371/672212_62501B5X1020_003RMP.pdf)

¹⁰² Health Sciences Authority (HSA). (2022, February 28). *HSA Singapore the First National Regulatory Authority Awarded the Highest Recognition for an Advanced Medicines Regulatory System by the World Health Organization* [Press release].

¹⁰³ *WHO-UMC-HSA Inter-Regional Pharmacovigilance Training Workshop*. (2021).

Retrieved January 12, 2023, from

[https://www.singhealthdukenus.com.sg/research/ALL%20FILES/Events/2021/2021_](https://www.singhealthdukenus.com.sg/research/ALL%20FILES/Events/2021/2021_PV_%20Workshop_%20Programme_2021_%20Draft.pdf)

[PV_%20Workshop_%20Programme_2021_%20Draft.pdf](https://www.singhealthdukenus.com.sg/research/ALL%20FILES/Events/2021/2021_PV_%20Workshop_%20Programme_2021_%20Draft.pdf)

¹⁰⁴ Health Sciences Authority (HSA). (2022, February 3). *HSA Grants Interim Authorisation for PaxlovidTM, the First Oral Medicine for Treatment of COVID-19 Infection* [Press release]. <https://www.hsa.gov.sg/announcements/press-release/interimauth-paxlovid/>

¹⁰⁵ Health Sciences Authority (HSA). (2022, April 19). *HSA Grants Interim Authorisation for LAGEVRIO (Molnupiravir) for Treatment of COVID-19 Infection* [Press release].

[https://www.hsa.gov.sg/announcements/press-release/interimauth-lagevrio-](https://www.hsa.gov.sg/announcements/press-release/interimauth-lagevrio-molnupiravir)

[molnupiravir](https://www.hsa.gov.sg/announcements/press-release/interimauth-lagevrio-molnupiravir)

-
- ¹⁰⁶ Le, T. T., Nguyen, T. T. H., Nguyen, C., Tran, N. H., Tran, L. A., Nguyen, T. B., Nguyen, N., & Nguyen, H. A. (2019). Factors associated with spontaneous adverse drug reaction reporting among healthcare professionals in Vietnam. *Journal of Clinical Pharmacy and Therapeutics*, 45(1), 122–127. <https://doi.org/10.1111/jcpt.13037>
- ¹⁰⁷ Nguyen-Thi, H. Y., Do-Tran, M. T., Ngoc, T. L., Nguyen-Ngoc, T. T., & Le, N. D. T. (2021). Assessment of Knowledge, Attitude, and Practice in Adverse Drug Reaction Reporting of Healthcare Professionals in Vietnam: A Cross-Sectional Study. *Hospital Pharmacy*, 57(3), 392–401. <https://doi.org/10.1177/00185787211046864>
- ¹⁰⁸ Nguyen, K. D., Nguyen, P. T., Nguyen, H. A., Roussin, A., Montastruc, J. L., Bagheri, H., & Olsson, S. (2017). Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country. *Drug Safety*, 41(2), 151–159. <https://doi.org/10.1007/s40264-017-0598-y>
- ¹⁰⁹ One more drug Molnupiravir to treat COVID-19 is licensed domestically. (2022, May 24). Portal of the Ministry of Health About Covid-19 Pandemic. Retrieved January 12, 2023, from <https://covid19.gov.vn/them-1-thuoc-molnupiravir-dieu-tri-covid-19-san-xuat-trong-nuoc-duoc-cap-phep-171220524152144204.htm>
- ¹¹⁰ Ministry of Health. (2022, May 25). Vietnam has added Molnupiravir Stella 200 mg for COVID-19 treatment made in the country. <https://covid19.gov.vn/viet-nam-co-them-molnupiravir-stella-200-mg-dieu-tri-covid-19-san-xuat-trong-nuoc-17122052510174894.htm>

¹¹¹ Health ministry proposes easing access to Molnupiravir for COVID-19 patients. (2022).

Viet Nam News. <https://vietnamnews.vn/society/1163004/health-ministry-proposes-easing-access-to-molnupiravir-for-covid-19-patients.html>

¹¹² There is information about selling Molnupiravir at the pharmacy: The Drug

Administration of Vietnam urgently requests inspection, inspection and strict handling of violations. (2022). *SUCKHOEDOISONG*. <https://suckhoedoisong.vn/co-thong-tin-ban-molnupiravir-tai-nha-thuoc-cuc-quan-ly-duoc-yeu-cau-khan-truong-thanh-kiem-tra-xu-ly-nghiem-vi-pham-169220107091141685.htm>

¹¹³ Specialist Health Service. (2020). *Desk-Based Vaccine Capability and Gap Analysis:*

Pacific Island Countries. Retrieved January 12, 2023, from <https://www.dfat.gov.au/sites/default/files/dfat-foi-lex3832.pdf>

¹¹⁴ *World Bank Open Data / Data*. (n.d.). <https://data.worldbank.org/>

¹¹⁵ *Home / Statistics for Development Division*. (n.d.). <https://sdd.spc.int/>

¹¹⁶ TechNet-21. (n.d.). *How the mSupply electronic inventory management toolset is*

supporting the COVID-19 vaccine rollout; with Tonga case study [Slide show].

TechNet-21 Webinar. [https://www.technet-](https://www.technet-21.org/media/com_resources/trl/7142/multi_upload/Technet21_Presentation_16_9_VaccinesandmSupply_V1.2.pdf)

[21.org/media/com_resources/trl/7142/multi_upload/Technet21_Presentation_16_9_VaccinesandmSupply_V1.2.pdf](https://www.technet-21.org/media/com_resources/trl/7142/multi_upload/Technet21_Presentation_16_9_VaccinesandmSupply_V1.2.pdf)

-
- ¹¹⁷ Healthcare staff training in Solomon Islands to strengthen understanding of adverse events following immunisation. (2022, July 25). *Australian Regional Immunisation Alliance*. Retrieved January 13, 2023, from <https://regionalimmunisationalliance.org.au/healthcare-staff-training-solomon-islands-strengthen-understanding-adverse-events-following>
- ¹¹⁸ Ministry of Health of Vanuatu. (2020). *National Deployment and Vaccination Plan for COVID-19 Vaccines*. <https://www.adb.org/sites/default/files/linked-documents/50282-003-sd-07.pdf>
- ¹¹⁹ *An Act to protect public health by providing for the establishment of the Medicines and Therapeutics Committee and for the effective regulation of medicines in Kiribati to ensure their quality, safety, and efficacy*. (2018). <https://www.parliament.gov.ki/sites/default/files/2021-04/Medicines%20Bills%202018%20.pdf>
- ¹²⁰ Tuval. *Pharmacy and Therapeutic Products Act*. (2016). http://tuvalu.tradeportal.org/media//PharmacyandTherapeuticProductsAct2016_1.pdf
- ¹²¹ RNZ News. (2021, July 12). Over 1000 people in Tokelau, Cook Islands to get Covid-19 vaccine from NZ. *RNZ*. <https://www.rnz.co.nz/international/pacific-news/446745/over-1000-people-in-tokelau-cook-islands-to-get-covid-19-vaccine-from-nz>

-
- ¹²² Ministry of Health, New Zealand. (2022). *Interim report 2021 COVID-19 Vaccine Independent Safety Monitoring Board (CV-ISMB)*.
<https://www.health.govt.nz/system/files/documents/pages/cv-ismb-interim-report-updated-july-2022.pdf>
- ¹²³ Congress of the Federated States of Micronesia (CFSM). (2018). *TWENTIETH CONGRESS OF THE FEDERATED STATES OF MICRONESIA FOURTH REGULAR SESSION, 2018: A BILL FOR AN ACT*. Retrieved January 12, 2023, from https://www.c fsm.gov.fm/iframe/20%20congress/BILLS/C_B__No__20-195.pdf
- ¹²⁴ Puas, G., & Samo, M. (2021). Developing Pharmaceutical Legislation in the Federated States of Micronesia. *Pacific Research Program an Initiative of the Australian Aid Program*. <https://doi.org/10.25911/SXGT-QJ33>
- ¹²⁵ Directorate of Health and Social Affairs (DASS). (n.d.). *Vigilance: The DASS ensures the implementation of the vigilance system for health products*. Retrieved January 12, 2023, from <https://dass.gouv.nc/votre-sante-produits-de-sante-cosmetiques-etc/les-vigilances>
- ¹²⁶ Agency for the Regulation of Health and Social Action. (n.d.). *PATIENTS: Reporting adverse reactions*. Retrieved January 12, 2023, from <https://www.service-public.pf/arass/patients/>

-
- ¹²⁷ *State and Territory Services in Wallis and Futuna*. (n.d.). Retrieved January 11, 2023, from <https://www.wallis-et-futuna.gouv.fr/Politiques-publiques/Sante>
- ¹²⁸ INTEGRE. (2016). *ACTION PLAN PITCAIRN*. Retrieved January 12, 2023, from https://integre.spc.int/images/pdf/INTEGRE/telechargements/Action_Plan_Pitcairn.pdf
- ¹²⁹ Therapeutic Goods Administration (TGA). (n.d.). *The Indo-Pacific Regulatory Strengthening Program*. Retrieved January 12, 2023, from <https://indopacifichealthsecurity.dfat.gov.au/investments/indo-pacific-regulatory-strengthening-program>
- ¹³⁰ Therapeutic Goods Administration (TGA). (2021, December 2). *Strengthening pharmacovigilance for COVID-19 vaccines in the Philippines*. Retrieved January 12, 2023, from <https://indopacifichealthsecurity.dfat.gov.au/news-insights/strengthening-pharmacovigilance-covid-19-vaccines-philippines>
- ¹³¹ Pharmaceuticals and Medical Devices Agency (PMDA). (2022, June 13). *The 2nd Malaysia-Japan Symposium*. Retrieved January 12, 2023, from <https://www.pmda.go.jp/english/symposia/0237.html>

-
- ¹³² Pharmaceuticals and Medical Devices Agency (PMDA). (n.d.). *Report of the PMDA-ATC COVID-19 related Medical Products Webinar 2022 for DAV, Vietnam*. Retrieved January 12, 2023, from <https://www.pmda.go.jp/english/symposia/0233.html>
- ¹³³ Asia-Pacific Economic Cooperation. (n.d.). *Pharmacovigilance*. Retrieved January 12, 2023, from <https://www.apec.org/rhsc/rhsc-priority-work-areas/pharmacovigilance>
- ¹³⁴ Pharmaceuticals and Medical Devices Agency (PMDA). (2022). *Report of the PMDA-ATC Pharmacovigilance Webinar 2022*. Retrieved January 13, 2023, from <https://www.pmda.go.jp/english/symposia/0232.html>
- ¹³⁵ Council For International Organizations Of Medical Sciences (CIOMS). (n.d.). *PHARMACOVIGILANCE*. Retrieved January 12, 2023, from <https://cioms.ch/pharmacovigilance/>
- ¹³⁶ Drug Information Association (DIA). (n.d.). Retrieved January 12, 2023, from <https://www.diaglobal.org/>
- ¹³⁷ Drug Information Association. (n.d.). *DIA Learning Solutions: Safety & Pharmacovigilance*. Retrieved January 12, 2023, from <https://www.diaglobal.org/en/learning-solutions/safety-and-pharmacovigilance>
- ¹³⁸ International Coalition of Medicines Regulatory Authorities (ICMRA). (2018, December 3). *Pharmacovigilance Increasing Adverse Event Reporting subproject*. Retrieved

January 13, 2023, from

<https://www.icmra.info/drupal/en/strategicinitatives/pharmacovigilance/IAER>

¹³⁹ International Coalition of Medicine. (n.d.). *Increasing Adverse Event Reporting (IAER)*

subproject: Survey report. Retrieved January 13, 2023, from

<https://www.icmra.info/drupal/sites/default/files/2018->

[12/ICMRA%20PhV%20IAER%20SubWG%20Survey%20Final%20Report.pdf](https://www.icmra.info/drupal/sites/default/files/2018-12/ICMRA%20PhV%20IAER%20SubWG%20Survey%20Final%20Report.pdf)

¹⁴⁰ *Western Pacific / ISOP*. (n.d.). Retrieved January 13, 2023, from

<https://isoponline.org/chapters/western-pacific/>

¹⁴¹ World Health Organization. (2015). *WHO PHARMACOVIGILANCE INDICATORS: A*

PRACTICAL MANUAL FOR THE ASSESSMENT OF PHARMACOVIGILANCE

SYSTEMS.

https://apps.who.int/iris/bitstream/handle/10665/186642/9789241508254_eng.pdf

¹⁴² Olsson, S., Pal, S. N., Stergachis, A., & Couper, M. (2010). Pharmacovigilance Activities

in 55 Low- and Middle-Income Countries. *Drug Safety*, 33(8), 689–703.

<https://doi.org/10.2165/11536390-000000000-00000>

¹⁴³ Huybrechts, K. F., Desai, R. J., Park, M., Gagne, J. J., Najafzadeh, M., & Avorn, J.

(2017). The Potential Return on Public Investment in Detecting Adverse Drug

Effects. *Medical Care*, 55(6), 545–551.

<https://doi.org/10.1097/mlr.0000000000000717>

-
- ¹⁴⁴ *ACT-Accelerator Outcomes Report, 2020-22 - World*. (2022, December 25). ReliefWeb.
<https://reliefweb.int/report/world/act-accelerator-outcomes-report-2020-22>
- ¹⁴⁵ Xueref, S., Daviaud, J., & Pal, S. (2013). The Global Fund and pharmacovigilance systems in resourcelimited settings. *The Lancet*, 381(9875), 1360.
[https://doi.org/10.1016/s0140-6736\(13\)60885-5](https://doi.org/10.1016/s0140-6736(13)60885-5)
- ¹⁴⁶ Kovacs, S. D., Mills, B. M., & Stergachis, A. (2017). Donor support for quality assurance and pharmacovigilance of anti-malarials in malaria-endemic countries. *Malaria Journal*, 16(1). <https://doi.org/10.1186/s12936-017-1921-x>
- ¹⁴⁷ Therapeutic Goods Administration (TGA). (2021b, July 26). *TGA international engagement strategy 2021-2025*. Retrieved January 11, 2023, from
<https://www.tga.gov.au/resources/publication/publications/tga-international-engagement-strategy-2021-2025>
- ¹⁴⁸ Uppsala Monitoring Centre. (n.d.). *AEFI reporting in the palm of your hand, anytime, anywhere*. <https://who-umc.org/pv-products/vigimobile/>
- ¹⁴⁹ *mSupply - Simple. Powerful*. (n.d.-b). <https://msupply.org.nz/mobile#293>
- ¹⁵⁰ Bouvy, J. C., Ebbers, H. C., Schellekens, H., & Koopmanschap, M. A. (2013). The Cost-Effectiveness of Periodic Safety Update Reports for Biologicals in Europe. *Clinical Pharmacology & Therapeutics*, 93(5), 433–442.
<https://doi.org/10.1038/clpt.2013.13>

-
- ¹⁵¹ World Health Organization. (2021). *WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products - Revision VI*.
<https://www.who.int/publications/i/item/9789240020245>
- ¹⁵² World Health Organization (WHO). (2019). *WHO GLOBAL BENCHMARKING TOOL PLUS (GBT+) FOR EVALUATION OF NATIONAL REGULATORY SYSTEM OF MEDICAL PRODUCTS: VIGILANCE (VL): INDICATORS AND FACT SHEETS*. Retrieved January 12, 2023, from https://cdn.who.int/media/docs/default-source/medicines/regulation-systems/gbt/03_gbt-_rev_vl-_ver_1_vl_nov_2019.pdf?sfvrsn=595bdab6_3&download=true
- ¹⁵³ World Health Organization. (2022, March 11). *Safety monitoring of molnupiravir for treatment of mild to moderate COVID-19 infection in low and middle-income countries using cohort event monitoring: a WHO study*. Retrieved January 11, 2023, from https://www.who.int/publications/i/item/WHO-2019-nCoV-Therapeutics-safety_monitoring-molnupiravir-2022.1
- ¹⁵⁴ Chan, C. L., Ang, P. S., & Li, S. C. (2017). A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms. *Drug Safety*, 40(6), 517–530. <https://doi.org/10.1007/s40264-017-0510-9>